In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1878-1887

  Lenz, Oliver ^a,b   Verbinnen, Thierry ^a,b   Lin, Tse I ^a,b   Vijgen, Leen ^a,b   Cummings, Maxwell D ^a,b   Lindberg, Jimmy ^c   Berke, Jan Martin ^a,b   Dehertogh, Pascale ^a,b   Fransen, Els ^a,b   Scholliers, Annick ^a,b   Vermeiren, Katrien ^a,b   Ivens, Tania ^a,b   Raboisson, Pierre ^a,b   Edlund, Michael ^c   Storm, Susan ^c   Vrang, Lotta ^c   De Kock, Herman ^a,b   Fanning, Gregory C ^a,b   Simmen, Kenneth A ^a,b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Pharmaceuticals Ltd   (Ireland)

^c MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATOVAQUONE; BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; TELAPREVIR; TMC 435350;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG COST; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS MUTATION; WILD TYPE;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MUTAGENESIS; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77951210464     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01452-09     Document Type: Article

References (54)

1. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190.
2. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
3. Burns, C. J., A. M. Del Vecchio, T. R. Bailey, B. A. Kulkarni, T. H. Faitg, S. R. Sherk, C. W. Blackledge, D. J. Rys, T. A. Lessen, J. Swestock, Y. Deng, T. J. Nitz, J. A. Reinhardt, H. Feng, and A. K. Saha. May 2004. Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases. PCT patent WO2004041201.
4. Chan, L., O. Pereira, T. J. Reddy, S. K. Das, C. Poisson, M. Courchesne, M. Proulx, A. Siddiqui, C. G. Yannopoulos, N. Nguyen-Ba, C. Roy, D. Nasturica, C. Moinet, R. Bethell, M. Hamel, L. L'Heureux, M. David, O. Nicolas, P. Courtemanche-Asselin, S. Brunette, D. Bilimoria, and J. Bédard. 2004. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2. Tertiary amides. Bioorg. Med. Chem. Lett. 14:797-800.
5. Cummings, M. D., J. Lindberg, T.-I. Lin, H. de Kock, O. Lenz, E. Lilja, S. Felländer, V. Baraznenok, S. Nyström, M. Nilsson, L. Vrang, M. Edlund, Å. Rosenquist, B. Samuelsson, P. Raboisson, and K. Simmen. 2010. Induced fit binding of the noncovalent macrocyclic inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew. Chem. Int. Ed. Engl. 49:1652-1655.
6. De Francesco, R., and A. Carfi. 2007. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59:1242-1262.
7. Ghobrial, R. M., R. Steadman, J. Gornbein, C. Lassman, C. D. Holt, P. Chen, D. G. Farmer, H. Yersiz, N. Danino, E. Collisson, A. Baquarizo, S. S. Han, S. Saab, L. I. Goldstein, J. A. Donovan, K. Esrason, and R. W. Busuttil. 2001. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann. Surg. 234:384-393.
8. Guidetti, R., D. Haigh, C. D. Hartley, P. D. Howes, F. Nerozzi, and S. A. Smith. May 2006. Preparation of 4-(methoxycarbonyl)pyrrolidine-2-carboxylic acid derivatives as hepatitis C virus inhibitors. PCT patent WO2006045613.
9. Harper, S., S. Avolio, B. Pacini, M. Di Filippo, S. Altamura, L. Tomei, G. Paonessa, S. Di Marco, A. Carfi, C. Giuliano, J. Padron, F. Bonelli, G. Migliaccio, R. De Francesco, R. Laufer, M. Rowley, and F. Narjes. 2005. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J. Med. Chem. 48:4547-4557.
10. He, Y., M. S. King, D. J. Kempf, L. Lu, H. B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla. 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 52:1101-1110.
11. Hézode, C., N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.-P. Bronowicki, M. Bourlière, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R. S. Kauffman, J. Alam, J.-M. Pawlotsky, S. Zeuzem, and PROVE2 Study Team. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850.
12. Johnson, V. A., F. Brun-Vézinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16:138-145.
13. Koev, G., and W. Kati. 2008. The emerging field of HCV drug resistance. Expert Opin. Invest. Drugs 17:303-319.
14. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624. (Pubitemid 32381503)
15. Kukolj, G., Y. Benhamou, M. P. Manns, M. Bourlière, S. Pol, M. Schuchmann, M. Cartier, D. Huang, L. Lagacé, G. Steinmann, and J. O. Stern. 2009. A potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol. 50:S347.
16. Kwo, P., E. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, M. Davis, J. Galati, S. Gordon, N. Ravendhran, L. Rossaro, F. Anderson, I. Jacobson, R. Rubin, K. Koury, C. Brass, E. Chaudhri, and J. Albrecht. 2009. HCV Sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron™ (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J. Hepatol. 50:S4.
17. Kwong, A. D., L. McNair, I. Jacobson, and S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8:522-531.
18. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A.-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M.-A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C.-L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
19. Lin, C., C. A. Gates, B. G. Rao, D. L. Brennan, J. R. Fulghum, Y.-P. Luong, J. D. Frantz, K. Lin, S. Ma, Y.-Y. Wei, R. B. Perni, and A. D. Kwong. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280: 36784-36791.
20. Lin, C., A. D. Kwong, and R. B. Perni. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord.-Drug Targets 6:3-16.
21. Lin, T.-I., O. Lenz, G. Fanning, T. Verbinnen, F. Delouvroy, A. Scholliers, K. Vermeiren, Å. Rosenquist, M. Edlund, B. Samuelsson, L. Vrang, H. de Kock, P. Wigerinck, P. Raboisson, and K. Simmen. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 53:1377-1385.
22. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
23. Liverton, N. J., S. S. Carroll, J. DiMuzio, C. Fandozzi, D. J. Graham, D. Hazuda, M. K. Holloway, S. W. Ludmerer, J. A. McCauley, C. J. McIntyre, D. B. Olsen, M. T. Rudd, M. Stahlhut, and J. P. Vacca. 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54:305-311.
24. Llinas-Brunet, M., M. D. Bailey, G. Bolger, C. Brochu, A.-M. Faucher, J. M. Ferland, M. Garneau, E. Ghiro, V. Gorys, C. Grand-Maitre, T. Halmos, N. Lapeyre-Paquette, F. Liard, M. Poirier, M. Rheaume, Y. S. Tsantrizos, and D. Lamarre. 2004. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J. Med. Chem. 47:1605-1608.
25. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019.
26. Lohmann, V., F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
27. Lu, L., T. J. Pilot-Matias, K. D. Stewart, J. T. Randolph, R. Pithawalla, W. He, P. P. Huang, L. L. Klein, H. Mo, and A. Molla. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266.
28. Malcolm, B. A., R. Liu, F. Lahser, S. Agrawal, B. Belanger, N. Butkiewicz, R. Chase, F. Gheyas, A. Hart, D. Hesk, P. Ingravallo, C. Jiang, R. Kong, J. Lu, J. Pichardo, A. Prongay, A. Skelton, X. Tong, S. Venkatraman, E. Xia, V. Girijavallabhan, and F. G. Njoroge. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50:1013-1020.
29. Manns, M., A. Muir, N. Adda, I. Jacobson, N. Afdhal, J. Heathcote, S. Zeuzem, H. Reesink, N. Terrault, M. Bsharat, S. George, J. McHutchison, and A. Di Bisceglie. 2009. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2A/B and ribavirin therapy: SVR results of the Prove3 study. J. Hepatol. 50:S379.
30. Manns, M., H. Reesink, C. Moreno, T. Berg, Y. Benhamou, Y. Horsmans, G. Dusheiko, R. Flisiak, P. Meyvisch, O. Lenz, V. Sekar, G. van't Klooster, K. Simmen, and R. Verloes. 2009. OPERA-1 trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J. Hepatol. 50:S7.
31. Manns, M. P., G. R. Foster, J. K. Rockstroh, S. Zeuzem, F. Zoulim, and M. Houghton. 2007. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6:991-1000.
32. Marcellin, P., H. Reesink, T. Berg, M. Cramp, R. Flisiak, H. Van Vlierberghe, R. Verloes, O. Lenz, M. Peeters, V. Sekar, and G. De Smedt. 2009. Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J. Hepatol. 50:S385.
33. McCown, M. F., S. Rajyaguru, S. Kular, N. Cammack, and I. Nájera. 2009. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 53:2129-2132.
34. McHutchison, J. G., G. T. Everson, S. C. Gordon, I. M. Jacobson, M. Sulkowski, R. Kauffman, L. McNair, J. Alam, A. J. Muir, and PROVE1 Study Team. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:1827-1838.
35. Mo, H., L. Lu, T. Pilot-Matias, R. Pithawalla, R. Mondal, S. Masse, T. Dekhtyar, T. Ng, G. Koev, V. Stoll, K. D. Stewart, J. Pratt, P. Donner, T. Rockway, C. Maring, and A. Molla. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49:4305-4314.
36. Nettles, R., C. Chien, E. Chung, A. Persson, M. Gao, M. Belema, N. A. Meanwell, M. P. DeMicco, T. C. Marbury, R. Goldwater, P. Northup, J. Coumbis, W. K. Kraft, M. R. Charlton, J. C. Lopez-Talavera, and G. Denise. 2008. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48:1025A.
37. Penin, F., J. Dubuisson, F. A. Rey, D. Moradpour, and J.-M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39:5-19.
38. Perni, R. B., S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y.-P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, and C. Lin. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909.
39. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F.-L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
40. Prongay, A. J., Z. Guo, N. Yao, J. Pichardo, T. Fischmann, C. Strickland, J. J. Myers, P. C. Weber, B. M. Beyer, R. Ingram, Z. Hong, W. W. Prosise, L. Ramanathan, S. S. Taremi, T. Yarosh-Tomaine, R. Zhang, M. Senior, R.-S. Yang, B. Malcolm, A. Arasappan, F. Bennett, S. L. Bogen, K. Chen, E. Jao, Y.-T. Liu, R. G. Lovey, A. K. Saksena, S. Venkatraman, V. Girijavallabhan, F. G. Njoroge, and V. Madison. 2007. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034). II. Key steps in structure-based optimization. J. Med. Chem. 50:2310-2318.
41. Raboisson, P., H. de Kock, Å. Rosenquist, M. Nilsson, L. Salvador-Oden, T.-I. Lin, N. Roue, V. Ivanov, H. Wähling, K. Wickström, E. Hamelink, M. Edlund, L. Vrang, S. Vendeville, W. Van de Vreken, D. McGowan, A. Tahri, L. Hu, C. Boutton, O. Lenz, F. Delouvroy, G. Pille, D. Surleraux, P. Wigerinck, B. Samuelsson, and K. Simmen. 2008. Structure-activity relationship study on a novel series of cyclopentane- containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 18:4853-4858.
42. Reesink, H. W., G. C. Fanning, K. Abou Farha, C. Weegink, A. Van Vliet, G. Van't Klooster, O. Lenz, F. Aharchi, K. Mariën, P. Van Remoortere, H. de Kock, F. Broeckaert, P. Meyvisch, E. Van Beirendonck, K. Simmen, and R. Verloes. 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913-921.
43. Sarrazin, C., J. Hong, S. Lim, X. Qin, S. Susser, B. Bradford, S. Porter, S. Zeuzem, and S. Seiwert. 2009. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2a/ribavirin. J. Hepatol. 50:S350.
44. Sarrazin, C., T. L. Kieffer, D. Bartels, B. Hanzelka, U. Müh, M. Welker, D. Wincheringer, Y. Zhou, H.-M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
45. Schmittgen, T. D., and K. J. Livak. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3:1101-1108.
46. Seiwert, S. D., S. W. Andrews, Y. Jiang, V. Serebryany, H. Tan, K. Kossen, P. T. R. Rajagopalan, S. Misialek, S. K. Stevens, A. Stoycheva, J. Hong, S. R. Lim, X. Qin, R. Rieger, K. R. Condroski, H. Zhang, M. G. Do, C. Lemieux, G. P. Hingorani, D. P. Hartley, J. A. Josey, L. Pan, L. Beigelman, and L. M. Blatt. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441.
47. Seiwert, S. D., J. Hon, S. R. Lim, T. Wang, H. Tan, and L. M. Blatt. 2007. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. J. Hepatol. 46:S244-S245.
48. Strader, D. B., T. Wright, D. L. Thomas, L. B. Seeff, and American Association for the Study of Liver Diseases. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
49. Tong, X., S. Bogen, R. Chase, V. Girijavallabhan, Z. Guo, F. G. Njoroge, A. Prongay, A. Saksena, A. Skelton, E. Xia, and R. Ralston. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177-185.
50. Tong, X., R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B. A. Malcolm. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70:28-38.
51. Tsantrizos, Y. S., G. Bolger, P. Bonneau, D. R. Cameron, N. Goudreau, G. Kukolj, S. R. LaPlante, M. Llinas-Brunet, H. Nar, and D. Lamarre. 2003. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 42:1356-1360.
52. Venkatraman, S., S. L. Bogen, A. Arasappan, F. Bennett, K. Chen, E. Jao, Y.-T. Liu, R. Lovey, S. Hendrata, Y. Huang, W. Pan, T. Parekh, P. Pinto, V. Popov, R. Pike, S. Ruan, B. Santhanam, B. Vibulbhan, W. Wu, W. Yang, J. Kong, X. Liang, J. Wong, R. Liu, N. Butkiewicz, R. Chase, A. Hart, S. Agrawal, P. Ingravallo, J. Pichardo, R. Kong, B. Baroudy, B. Malcolm, Z. Guo, A. Prongay, V. Madison, L. Broske, X. Cui, K.-C. Cheng, Y. Hsieh, J.-M. Brisson, D. Prelusky, W. Korfmacher, R. White, S. Bogdanowich-Knipp, A. Pavlovsky, P. Bradley, A. K. Saksena, A. Ganguly, J. Piwinski, V. Girijavallabhan, and F. G. Njoroge. 2006. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)- [[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49:6074-6086.
53. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.-G. Kräusslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
54. World Health Organization. 2010. Hepatitis C: disease3 burden. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/ diseases/viral-cancers/en/index2.html.